AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33587402 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 32
Study 33587402 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 32
Study 33587402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 32589632 — intervention group
Group type: EXPERIMENTAL
Intervention: Household Treatment group (all family members treated)
Number of subjects: 79
Study 32589632 — intervention group
Group type: COMPARATOR
Intervention: Individual Treatment group (only affected participants treated)
Number of subjects: 79
Study 32589632 — intervention group
Group type: EXPERIMENTAL
Intervention: Household Treatment group
Number of subjects: 79
Study 32589632 — intervention group
Group type: COMPARATOR
Intervention: Individual Treatment group
Number of subjects: 79
Study 36038262 — intervention group
Group type: EXPERIMENTAL
Intervention: Treg infusions (1 × 10^6 cells/kg) IV every 4 weeks and IL-2 (2 × 10^5 IU/m2) injections 3 times/week
Number of subjects: 9
Study 36038262 — intervention group
Group type: EXPERIMENTAL
Intervention: Treg infusions (2 × 10^6 cells/kg and 3 × 10^6 cells/kg) in OLE
Number of subjects: 9
Study 36038262 — intervention group
Group type: EXPERIMENTAL
Intervention: Treg/IL-2 treatments
Number of subjects: 9
Study 36038262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 33818395 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment app (including pelvic floor muscle training, bladder training, psychoeducation, lifestyle advice, tailored advice, exercise log, reinforcement messages, and reminders)
Number of subjects: 123
Study 33818395 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment app
Number of subjects: 123
Study 33818395 — intervention group
Group type: COMPARATOR
Intervention: Information app (control group)
Number of subjects: 123
Study 36476386 — intervention group
Group type: EXPERIMENTAL
Intervention: Online behavior change intervention with weekly individual online sessions for 12 weeks and an activity monitor
Number of subjects: 46
Study 36476386 — intervention group
Group type: COMPARATOR
Intervention: Online educational program (1 hour)
Number of subjects: 46
Study 36476386 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly individual online sessions for 12 weeks
Number of subjects: 46
Study 36476386 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitor with specific strategies
Number of subjects: 46
Study 33548765 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar rotation with extension subgroup
Number of subjects: 154
Study 33548765 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar rotation subgroup
Number of subjects: 154
Study 33548765 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 154
Study 33548765 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 154
Study 33548765 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender × test interaction
Number of subjects: 154
Study 33548765 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup × test interaction
Number of subjects: 154
Study 33548765 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup × gender interaction
Number of subjects: 154
Study 35452654 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of the angle of progression in addition to digital examination
Number of subjects: 45
Study 35452654 — intervention group
Group type: COMPARATOR
Intervention: Control group (digital examination only)
Number of subjects: 45
Study 33617184 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D model
Number of subjects: 3623
Study 33617184 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D-CDFI model
Number of subjects: 3623
Study 33617184 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D-CDFI-PW model
Number of subjects: 3623
Study 33617184 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN classifications
Number of subjects: 3623
Study 33617184 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D model (size comparison)
Number of subjects: 3623
Study 32004437 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1% 4 times a day for four weeks
Number of subjects: 64
Study 32004437 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1% 3 times a day for three weeks
Number of subjects: 64
Study 35172054 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir plus ritonavir
Number of subjects: 2246
Study 35172054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2246
Study 34117190 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention addressing living with a PCN tube, provided twice (before placement and at first tube change, 6 weeks later)
Number of subjects: 178
Study 34117190 — intervention group
Group type: COMPARATOR
Intervention: Standard instruction (control group)
Number of subjects: 178
Study 32049772 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric HIV disclosure intervention
Number of subjects: 446
Study 32049772 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 446
Study 35022779 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19-directed therapies
Number of subjects: 424
Study 35022779 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroids
Number of subjects: 424
Study 35022779 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 424
Study 35724261 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced mobility
Number of subjects: 1319
Study 35724261 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of deep vein thrombosis
Number of subjects: 1319
Study 35724261 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheterization of veins on the back of the hand
Number of subjects: 1319
Study 35724261 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 1319
Study 35724261 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Potassium Clavulanate
Number of subjects: 1319
Study 35724261 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole Sodium
Number of subjects: 1319
Study 34470831 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose (100 mg biweekly, total 2 grams)
Number of subjects: 142
Study 34470831 — intervention group
Group type: COMPARATOR
Intervention: Ferric carboxymaltose (500 mg every 10 weeks, total 2 grams)
Number of subjects: 142
Study 34470831 — intervention group
Group type: COMPARATOR
Intervention: Ferric carboxymaltose
Number of subjects: 142
Study 34470831 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis stimulating agent dosing
Number of subjects: 142
Study 34470831 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 142
Study 32664946 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month structured exercise training (n=50)
Number of subjects: 100
Study 32664946 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care for detecting cardiac dysfunction (resting left-ventricular ejection fraction assessed from 3-dimensional echocardiography)
Number of subjects: 100
Study 32664946 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (n=50)
Number of subjects: 100
Study 35555966 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of triamcinolone acetonide
Number of subjects: 36
Study 35555966 — intervention group
Group type: COMPARATOR
Intervention: Fractional CO2 laser therapy followed by topical application of the drug for six sessions
Number of subjects: 36
Study 33059771 — intervention group
Group type: EXPERIMENTAL
Intervention: Adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac, 3 μg/0.5 mL (600 SU per dose), two doses IM with a two-week interval.
Number of subjects: 13060
Study 33059771 — intervention group
Group type: COMPARATOR
Intervention: Placebo containing aluminium hydroxide in a 0.5 mL solution, two doses IM with a two-week interval.
Number of subjects: 13060
Study 35304977 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of 200 mg cyclosporine
Number of subjects: 27
Study 35304977 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of 600 mg quinidine
Number of subjects: 27
Study 32265508 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 0
Study 32265508 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study 33687763 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab with etoposide and carboplatin
Number of subjects: 0
Study 33687763 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab with etoposide and either cisplatin or carboplatin
Number of subjects: 0
Study 33687763 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (etoposide and carboplatin or cisplatin)
Number of subjects: 0
Study 33356487 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT+SSRI
Number of subjects: 40
Study 33356487 — intervention group
Group type: EXPERIMENTAL
Intervention: ERP+SSRI
Number of subjects: 40
Study 33356487 — intervention group
Group type: COMPARATOR
Intervention: SSRI-only
Number of subjects: 40
Study 32884939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS)
Number of subjects: 0
Study 32884939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting cancer-specific survival (CSS)
Number of subjects: 0
Study 32884939 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration curve of the nomogram
Number of subjects: 0
Study 32884939 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision curve analyses (DCAs)
Number of subjects: 0
Study 36471257 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 774
Study 36471257 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 774
Study 36471257 — intervention group
Group type: COMPARATOR
Intervention: Postoperative adjuvant therapy (no therapy)
Number of subjects: 774
Study 33773120 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (up to 2.5 mg three times per day)
Number of subjects: 226
Study 33773120 — intervention group
Group type: COMPARATOR
Intervention: PDE5i (oral sildenafil [≥60 mg per day] or oral tadalafil [20–40 mg per day])
Number of subjects: 226
Study 33773120 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 226
Study 33773120 — intervention group
Group type: COMPARATOR
Intervention: PDE5i
Number of subjects: 226
Study 32546647 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint blockade (ICB) therapy
Number of subjects: 0
Study 32546647 — intervention group
Group type: COMPARATOR
Intervention: IDO enzyme inhibitor treatment
Number of subjects: 0
Study 35991780 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Controlled (PC) ventilation
Number of subjects: 40
Study 35991780 — intervention group
Group type: COMPARATOR
Intervention: Volume-Controlled (VC) ventilation
Number of subjects: 40
Study 33580944 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (30 mg/kg, six doses each 5 mg/kg, biweekly for 3 weeks)
Number of subjects: 100
Study 33580944 — intervention group
Group type: COMPARATOR
Intervention: Miltefosine (2.5 mg/kg or 100 mg/day for 12 weeks)
Number of subjects: 100
Study 35112516 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt and date palm
Number of subjects: 0
Study 35112516 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 32282034 — intervention group
Group type: COMPARATOR
Intervention: Telephone support
Number of subjects: 1155
Study 32282034 — intervention group
Group type: COMPARATOR
Intervention: SMS support
Number of subjects: 1155
Study 32282034 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1155
Study 35925752 — intervention group
Group type: EXPERIMENTAL
Intervention: 5:2 fasting diet
Number of subjects: 61
Study 35925752 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg/day liraglutide
Number of subjects: 61
Study 32012966 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Home Training (IHT)
Number of subjects: 0
Study 32012966 — intervention group
Group type: COMPARATOR
Intervention: Gym Group Training (GGT)
Number of subjects: 0
Study 32391744 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory impairment recovery (measured by EmNSA-UE)
Number of subjects: 94
Study 32391744 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor recovery (measured by FM-UE)
Number of subjects: 94
Study 32391744 — intervention group
Group type: EXPERIMENTAL
Intervention: Time progression
Number of subjects: 94
Study 32391744 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe somatosensory impairment at baseline
Number of subjects: 94
Study 36375318 — intervention group
Group type: EXPERIMENTAL
Intervention: Power visual-motor illusion
Number of subjects: 20
Study 36375318 — intervention group
Group type: COMPARATOR
Intervention: Standard visual-motor illusion
Number of subjects: 20
Study 32893049 — intervention group
Group type: EXPERIMENTAL
Intervention: FERM/scGOS/lcFOS
Number of subjects: 350
Study 32893049 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 350
Study 32893049 — intervention group
Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS
Number of subjects: 350
Study 32893049 — intervention group
Group type: EXPERIMENTAL
Intervention: FERM
Number of subjects: 350
Study 32828393 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotin supplementation at 0.3 mg/L (T1) and 0.45 mg/L (T2) in drinking water for older hens (53-56 weeks)
Number of subjects: 120
Study 32828393 — intervention group
Group type: COMPARATOR
Intervention: No biotin (T0)
Number of subjects: 120
Study 32828393 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotin supplementation (T1 and T2)
Number of subjects: 120
Study 35986471 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA with 2% Chlorhexidine Gluconate (CHX)
Number of subjects: 40
Study 35986471 — intervention group
Group type: COMPARATOR
Intervention: MTA alone
Number of subjects: 40
Study 33600105 — intervention group
Group type: EXPERIMENTAL
Intervention: 25° semisitting position
Number of subjects: 38
Study 33600105 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 38
Study 32092343 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 months androgen suppression (AS)
Number of subjects: 1051
Study 32092343 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate brachytherapy boost (HDRB)
Number of subjects: 1051
Study 32092343 — intervention group
Group type: COMPARATOR
Intervention: 66 Gy external beam radiation therapy (EBRT)
Number of subjects: 1051
Study 32092343 — intervention group
Group type: COMPARATOR
Intervention: 70 Gy external beam radiation therapy (EBRT)
Number of subjects: 1051
Study 32092343 — intervention group
Group type: COMPARATOR
Intervention: 74 Gy external beam radiation therapy (EBRT)
Number of subjects: 1051
Study 32092343 — intervention group
Group type: COMPARATOR
Intervention: 46 Gy EBRT plus HDRB
Number of subjects: 1051
Study 36128557 — intervention group
Group type: EXPERIMENTAL
Intervention: Trusilk R
Number of subjects: 129
Study 36128557 — intervention group
Group type: COMPARATOR
Intervention: Mersilk R
Number of subjects: 129
Study 36128557 — intervention group
Group type: EXPERIMENTAL
Intervention: Trusilk R and Mersilk R
Number of subjects: 129
Study 32220252 — intervention group
Group type: COMPARATOR
Intervention: Telephone intervention with 30 days of continuous phone support and two scheduled phone calls after discharge.
Number of subjects: 0
Study 32220252 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving usual care.
Number of subjects: 0
Study 32220252 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention.
Number of subjects: 0
Study 33550619 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 96
Study 33550619 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 96
Study 32030911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention (LI)
Number of subjects: 210
Study 32030911 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 210
Study 36184124 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotegrast methyl 480 mg
Number of subjects: 48
Study 36184124 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotegrast methyl 960 mg
Number of subjects: 48
Study 36184124 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 48
Study 36184124 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotegrast methyl (concentration-response analysis)
Number of subjects: 48
Study 33131460 — intervention group
Group type: EXPERIMENTAL
Intervention: CMJ performed at 60°
Number of subjects: 16
Study 33131460 — intervention group
Group type: EXPERIMENTAL
Intervention: CMJpref
Number of subjects: 16
Study 33131460 — intervention group
Group type: COMPARATOR
Intervention: CMJrefer
Number of subjects: 16
Study 32797382 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal HIV testing and treatment (UTT) including home-based and mobile testing, active linkage to care, rapid ART start, and enhanced male circumcision services.
Number of subjects: 30
Study 32797382 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal HIV testing and treatment (UTT)
Number of subjects: 30
Study 34002974 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-second static hamstring muscle stretch
Number of subjects: 100
Study 34002974 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-second static hamstring muscle stretch
Number of subjects: 100
Study 34002974 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham stretch for 20 seconds)
Number of subjects: 100
Study 32536075 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Professional Life Scale of Nurses
Number of subjects: 242
Study 32536075 — intervention group
Group type: EXPERIMENTAL
Intervention: Self Rating Depression Scale
Number of subjects: 242
Study 32536075 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regression analysis
Number of subjects: 242
Study 35997234 — intervention group
Group type: EXPERIMENTAL
Intervention: L-menthol ingestion (M-IG)
Number of subjects: 13
Study 35997234 — intervention group
Group type: EXPERIMENTAL
Intervention: L-menthol mouth rinsing (M-MR)
Number of subjects: 13
Study 34274407 — intervention group
Group type: EXPERIMENTAL
Intervention: G/M (3 months glargine followed by 9 months metformin)
Number of subjects: 221
Study 34274407 — intervention group
Group type: EXPERIMENTAL
Intervention: MET (12 months metformin)
Number of subjects: 221
Study 32192644 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (75 or 150 mg every 2 weeks)
Number of subjects: 281
Study 32192644 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 281
Study 35236763 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume recruitment (LVR) twice daily for 2 years
Number of subjects: 66
Study 35236763 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 66
Study 32798224 — intervention group
Group type: EXPERIMENTAL
Intervention: fIPV
Number of subjects: 250
Study 32798224 — intervention group
Group type: COMPARATOR
Intervention: IPV
Number of subjects: 250
Study 35140347 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of the µ‐opioid agonist morphine sulfate
Number of subjects: 80
Study 35140347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 33771357 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated positive end-expiratory pressure (PEEP)
Number of subjects: 82
Study 33771357 — intervention group
Group type: COMPARATOR
Intervention: Fixed positive end-expiratory pressure (PEEP) of 5 cmH2O
Number of subjects: 82
Study 35974938 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (1000 mg)
Number of subjects: 102
Study 35974938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (1000 mg)
Number of subjects: 102
Study 35974938 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (250 mg)
Number of subjects: 102
Study 33689731 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (5 mg TDS, up-titrated to 30 mg/day after one week)
Number of subjects: 1375
Study 33689731 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.05 mg BD, up-titrated to 0.2 mg/day after one week)
Number of subjects: 1375
Study 33689731 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 1375
Study 33689731 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 1375
Study 33689731 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Number of subjects: 1375
Study 32930386 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (n = 2029)
Number of subjects: 4052
Study 32930386 — intervention group
Group type: COMPARATOR
Intervention: Control arm without intervention (n = 2023)
Number of subjects: 4052
Study 32930386 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical modeling
Number of subjects: 4052
Study 32385678 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced PrEP (enPrEP) adherence support including peer navigation, in-person/online support groups, and SMS messages
Number of subjects: 204
Study 32385678 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (sPrEP)
Number of subjects: 204
Study 33307900 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-ACT program
Number of subjects: 430
Study 33307900 — intervention group
Group type: EXPERIMENTAL
Intervention: DOT-only for 6-8 weeks
Number of subjects: 430
Study 33307900 — intervention group
Group type: COMPARATOR
Intervention: Asthma education (AE) attention control
Number of subjects: 430
Study 32179023 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention to improve vaccination rates including designation of an immunization champion, purchasing vaccines, guidance on storage and management, routine identification of eligible patients, standing orders for vaccination, and vaccine administration.
Number of subjects: 40000
Study 35504988 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 0
Study 35504988 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram incorporating marital status, age, grade, tumor size, surgery of primary site, surgery of lymph node and metastatic
Number of subjects: 0
Study 32414386 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoadsorption (HA) device
Number of subjects: 18